Dual-targeting exosomes for improved drug delivery in breast cancer

Nanomedicine (Lond). 2023 Mar;18(7):599-611. doi: 10.2217/nnm-2022-0328. Epub 2023 May 17.

Abstract

Aims: The authors investigated whether displaying more than one homing peptide enhanced the tumor-targeting efficiency of exosomes. Materials & methods: Exosomes from human embryonic kidney cells (HEK293F) were engineered to display either mono- or dual-tumor-penetrating peptides, iRGD and tLyp1. Exosomes were purified via tangential flow filtration followed by ultracentrifugation. Results: When loaded with doxorubicin (Dox), the dual iRGD-tLyp1 exosomes strongly enhanced Dox uptake in both MCF-7 and MDA-MB-231 breast cancer cell lines, superior to single iRGD or tLyp1 exosomes. The dual iRGD-tLyp1 exosomal Dox was also the most potent, with IC50/GI50 values being 3.7-17.0-times lower than those of free Dox and other exosomal Dox. Conclusion: Selecting appropriate combinatorial homing peptides could be an approach for future precision nanomedicine.

Keywords: breast cancer; doxorubicin; exosomes; gene/drug delivery; iRGD; nanomedicine; tLyp1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Cell Line, Tumor
  • Doxorubicin / pharmacology
  • Drug Delivery Systems
  • Exosomes*
  • Female
  • Humans
  • Peptides

Substances

  • Doxorubicin
  • Peptides